All In Biotech

Drug Trial Radar · NCT07415954

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Apr 17, 2026

Primary completion

Sep 3, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • NNC0662-0419Drug

    NNC0662-0419 will be administered subcutaneously.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously.

  • PlaceboDrug

    Placebo will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycated haemoglobin (HbA1c) (week 16)Time frame: From baseline (week 0) to week 16
  2. Change in HbA1c (week 28)Time frame: From baseline (week 0) to week 28
  3. Change in HbA1c (week 40)Time frame: From baseline (week 0) to week 40

Locations

63 sites in 10 countries. Site status is shown where the registry gives one.

  • First Valley Medical Group

    Lancaster, California · Recruiting

  • Torrance Clinical Research Institute, Inc.

    Lomita, California · Recruiting

  • Ark Clinical Research

    Long Beach, California · Recruiting

  • Pacific Clinical Studies

    Los Alamitos, California · Recruiting

  • Wetlin Research Associates, Inc.

    San Diego, California · Recruiting

  • Diablo Clinical Research, Inc.

    Walnut Creek, California · Recruiting

  • Encore Medical Research LLC

    Hollywood, Florida · Recruiting

  • Bioclinical Research Alliance

    Miami, Florida · Recruiting

  • South Broward Research LLC

    Miramar, Florida · Recruiting

  • West Orange Endocrinology

    Ocoee, Florida · Not yet recruiting

  • Encore Medical Research of Weston

    Weston, Florida · Recruiting

  • Elite Clinical Trials

    Blackfoot, Idaho · Recruiting

  • Cedar-Crosse Research Center

    Chicago, Illinois · Recruiting

  • Brigham & Women's Hospital

    Boston, Massachusetts · Not yet recruiting

  • Headlands Research

    Springfield, Missouri · Recruiting

  • PharmQuest

    Greensboro, North Carolina · Recruiting

  • Piedmont Healthcare Statesville

    Statesville, North Carolina · Recruiting

  • Providence Center for Clinical Research

    Dayton, Ohio · Recruiting

  • CNS Healthcare

    Memphis, Tennessee · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • JCCT- Juno NW Houston

    Houston, Texas · Recruiting

  • Consano Clinical Research, LLC

    Shavano Park, Texas · Recruiting

  • Frontier Clinical Research - Kingwood

    Kingwood, West Virginia · Not yet recruiting

  • Opca bolnica Karlovac

    Karlovac, Croatia · Recruiting

  • Poliklinika SLAVONIJA OSIJEK

    Osijek, Croatia · Recruiting

  • Opca bolnica Varazdin_Endocrinology

    Varaždin, Croatia · Recruiting

  • Poliklinika Solmed

    Zagreb, Croatia · Recruiting

  • Debreceni Egyetem

    Debrecen, Hungary · Not yet recruiting

  • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ

    Szeged, Csongrád-Csanád, Hungary · Not yet recruiting

  • Debreceni Egyetem

    Debrecen, Hajdú-Bihar, Hungary · Not yet recruiting

  • Akaicho Clinic_Internal medicine

    Chiba-shi, Chiba, Japan · Active not recruiting

  • Naka Kinen Clinic_Internal medicine

    Ibaraki, Japan · Active not recruiting

  • Soka Sugiura Internal Medicine Clinic

    Soka-shi, Saitama, Japan · Active not recruiting

  • Tokyo-Eki Center-building Clinic_Internal Medicine

    Tokyo, Japan · Active not recruiting

  • ToCROM Clinic_Internal Medicine

    Tokyo, Japan · Active not recruiting

  • Terpa Sp. z o.o. Sp. k.

    Lublin, Poland · Not yet recruiting

  • Formed 2 Sp. z o.o.

    Oświęcim, Poland · Recruiting

  • PANSTWOWY INSTYTUT MEDYCZNY MSWiA

    Warsaw, Poland · Recruiting

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko

    Zabrze, Poland · Recruiting

  • "Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik

    Bialystok, Podlaskie Voivodeship, Poland · Recruiting

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.